PDF factsheet
      Z

cholesterol lowering intervention in cardiovascular prevention for primary prevention, clinical trials results

atorvastatin versus placebo
ASCOT, 2003
atorvastatin 10mg/d
versus
placebo
hypertensive patients aged 40-79 years with at least three other cardiovascular risk factorsdouble blind
Follow-up duration: 3.3 years
UK et Scandinavie
ASPEN (primary prevention sub group), 2006
atorvastatin 10mg
versus
placebo
subjects with type 2 diabetes and LDL cholesterol levels below contemporary guideline targets; primary prevention subgroup double blind
Follow-up duration: 4 year
14 countries
CARDS, 2004
NCT00327418
atorvastatin 10mg/d
versus
placebo
patients with type 2 diabetes without high concentrations of LDL-cholesterol and at least one of the following: retinopathy, albuminuria, current smoking, or hypertension.double blind
Follow-up duration: 3.9 years
UK, Irelande
Mohler, 2003
atorvastatin (10 mg per day)
versus
placebo
patients with intermittent claudicationdouble blind
Follow-up duration: 12 months
fluvastatin versus placebo
ALERT, 2003
fluvastatin 40 mg daily
versus
placebo
renal transplant recipients with total cholesterol 4.0-9.0 mmol/Ldouble-blind
Follow-up duration: 5.1 years
Belgium, Denmark, Finland, Germany, Norway,
BCAPS, 2001
fluvastatin 40 mg once daily
versus
placebo
subjects who had carotid plaque but no symptoms of carotid artery diseasedouble-blind
Follow-up duration: 3.0 years
Sweden
HYRIM, 2005
fluvastatin 40 mg daily
versus
placebo
drug-treated hypertensive men aged 40-74 years with total cholesterol 4.5-8.0 mmol/L, triglycerides <4.5 mmol/L, body mass index 25-35 kg/m2, and a sedentary lifestyledouble blind
Follow-up duration: 4 year
Norway
lovastatin versus placebo
ACAPS, 1994
NCT00000469
lovastatin 20mg daily
versus
placebo
men and women, 40 to 79 years old, with early carotid atherosclerosis and moderately elevated LDL cholesterol.double blind
Follow-up duration: 2.8 years
USA
AFCAPS/TexCAPS, 1998
lovastatin 20-40 mg/d
versus
placebo
men and women without clinically evident atherosclerotic cardiovascular disease with average total cholesterol (TC) and LDL-C levels and below-average high-density lipoprotein cholesterol (HDL-C) levelsdouble blind
Follow-up duration: 5.2 years
USA
pravastatin versus control
FAST Fukuoka pravastatin, 2002
pravastatin 10 mg/day
versus
control group (diet alone)
asymptomatic hypercholesterolemic patients open
Follow-up duration: 2 years
Japan
MEGA, 2006
NCT00211705
pravastatin 10 mg daily (20 mg per day if the total cholesterolconcentration did not decrease to 5·69 mmol/L or less)
versus
control
patients with hypercholesterolaemia (total cholesterol 5·69–6·98 mmol/L) and no history of coronary heart disease or strokeopen, blind assessment
Follow-up duration: 5.3 y
Japan
pravastatin versus placebo
CAIUS, 1996
pravastatin 40mg/d
versus
placebo
asymptomatic patients with hypercholesterolemia and at least one 1.3 < IMT < 3.5 mm in the carotid arteriesdouble blind
Follow-up duration: 3 years
Italy
KAPS, 1995
pravastatin 40mg/d
versus
placebo
Hypercholesterolemics men with serum LDL-C > or = 4.0 mmol/L and total cholesterol < 7.5 mmol/Ldouble blind
Follow-up duration: 3 years
Finland
PHYLLIS, 2004
pravastatin (40 mg per day)
versus
placebo
hypertensive, hypercholesterolemic patients with asymptomatic carotid atherosclerosis double-blind
Follow-up duration: 2.6 y
Italy
PMSG, 1993
pravastatin 20 mg once daily
versus
placebo
patients with hypercholesterolemia(serum total cholesterol concentrations of 5.2 to 7.8 mmol/liter) and > or = 2 additional risk factors for atherosclerotic coronary artery diseasedouble blind
Follow-up duration: 26 weeks
PROSPER (primary prevention subgroup), 2002
pravastatin 40mg/d
versus
placebo
men and women aged 70-82 years with a history of, or risk factors for, vascular disease; primary prevention subgroup double blind
Follow-up duration: 3.2 years
Ecosse, Irelande, Pays bas
WOSCOPS, 1995
pravastatine 40 mg daily
versus
placebo
men aged 45-64 yr with no history of myocardial infarction and with raised plasma cholesterol levels (LDL cholesterol of at least 155 mg/dL, total cholesterol of at least 252 mg/dL) double blind
Follow-up duration: 4.9 years
Scotland
pravastatin versus usual care
ALLHAT, 2002
NCT00000542
pravastatin 40mg/d
versus
usual care
aged 55 years or older, moderately hypercholesterolemic, hypertensive participants with at least 1 additional CHD risk factoropen
Follow-up duration: 4.8 years
USA, Puerto Rico, Canada
KLIS, 2000
pravastatin 10-20 mg/day
versus
conventional treatment
Japanese men aged 45-74 years with serum total cholesterol of > or = 220 mg/dl (5.69 mmol/l), primary prevenionopen
Follow-up duration: 5 years
Japan
rosuvastatin versus placebo
HOPE 3, 2016
NCT00468923
rosuvastatin 10 mg per day
versus
placebo
subjects who did not have cardiovascular disease and were at intermediate riskdouble-blind
Follow-up duration: 5.6 years
21 countries
JUPITER, 2008
NCT00239681
rosuvastatin 20 mg daily
versus
placebo
apparently healthy individuals with low LDL-cholesterol levels of less than 130 mg per deciliter but elevated C-reactive-protein (high-sensitivity C-reactive protein levels of 2.0 mg per liter or higher)double blind
Follow-up duration: median 1.9 year
26 countries
simvastatin versus placebo
HPS (diabetic primary prevention sub group), 2003
simvastatin 40 mg/d
versus
placebo
adults (aged 40-80 years) with diabetes (primary prevention subgroup) double blind
Follow-up duration: 5 years
UK

  Options


in first

in second

  Filter